American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis

Wiley - Tập 59 Số 6 - Trang 762-784 - 2008
Kenneth G. Saag1, Gim Gee Teng1, Nivedita M. Patkar1, Jeremy Anuntiyo2, Catherine Finney2, Jeffrey R. Curtis1, Harold E. Paulus2, Amy S. Mudano1, Maria Pisu1, Mary Elkins-Melton1, Ryan C. Outman1, Jeroan J. Allison1, Maria Suarez Almazor3, S. Louis Bridges1, W. Winn Chatham1, Marc C. Hochberg4, Catherine H. MacLean5, Ted R. Mikuls6, Larry W. Moreland7, Hani El‐Gabalawy5, Anthony Turkiewicz1, Daniel E. Furst2
1University of Alabama - Birmingham
2University of California-Los Angeles
3University of Texas MD Anderson, Houston,
4University of Maryland-Baltimore
5University of California, Los Angeles, RAND Corporation, Santa Monica, and West Los Angeles VAMC
6University of Nebraska, Omaha
7University of Pittsburgh, Pittsburgh, Pennsylvania

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1001/jama.289.24.3229

10.1056/NEJMct055183

10.1002/art.10148

The Appraisal of Guidelines for Research and Evaluation (AGREE) Collaboration. Introduction to the AGREE Collaboration.2001. URL:www.agreecollaboration.org.

Fitch K, 2001, The RAND/UCLA Appropriateness Method user's manual

10.1016/0197-2456(95)00134-4

Wells GA, 1999, The Newcastle‐Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta‐analyses

10.1136/ard.2004.028886

10.1016/j.rdc.2005.09.005

10.1002/art.21235

10.1002/art.1780380602

Pincus T, 2005, The American College of Rheumatology (ACR) core data set and derivative “patient only” indices to assess rheumatoid arthritis, Clin Exp Rheumatol, 23, S109

Wells GA, 2005, Minimal disease activity for rheumatoid arthritis: a preliminary definition, J Rheumatol, 32, 2016

Wolfe F, 2005, A composite disease activity scale for clinical practice, observational studies, and clinical trials: the Patient Activity Scale (PAS/PAS‐II), J Rheumatol, 32, 2410

10.1002/art.21494

10.1007/s10067-006-0275-5

10.1007/s10067-006-0343-x

10.1136/ard.2005.041376

10.1136/ard.62.2.120

10.1136/ard.62.5.427

10.1136/ard.61.4.290

10.1136/ard.2003.010611

10.1136/ard.62.7.611

10.1136/ard.61.12.1055

10.1136/ard.36.3.274

Cohen JD, 2006, Health Assessment Questionnaire score is the best predictor of 5‐year quality of life in early rheumatoid arthritis, J Rheumatol, 33, 1936

10.1093/rheumatology/32.8.717

10.1136/ard.45.5.373

10.1002/1529-0131(199809)41:9<1571::AID-ART7>3.0.CO;2-R

10.1002/1529-0131(199806)41:6<1072::AID-ART14>3.0.CO;2-G

10.1093/rheumatology/32.10.899

10.1016/j.jamcollsurg.2005.07.009

10.1177/0272989X04264212

10.1016/S0895-4356(01)00365-1

Hunt SA, 2005, ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure), Circulation, 112, e154

10.1093/rheumatology/kei024

10.1185/030079906X80341

Wendt T, 1999, Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis, Eur J Med Res, 4, 442

10.1002/art.1780340805

10.1002/art.21018

10.1016/0049-0172(91)90047-4

Rau R, 1991, A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis, J Rheumatol, 18, 328

10.1136/ard.58.4.220

10.1093/rheumatology/36.10.1082

10.1002/art.1780350802

10.1093/rheumatology/33.11.1049

10.1056/NEJM199605163342002

10.1001/archinte.159.21.2542

10.7326/0003-4819-137-9-200211050-00007

10.1002/art.1780381111

10.1016/S0140-6736(98)09403-3

10.1093/rheumatology/30.6.451

10.1016/S0002-9343(99)80399-4

10.7326/0003-4819-119-11-199312010-00002

10.1002/1529-0131(200110)44:10<2235::AID-ART385>3.0.CO;2-A

10.1136/ard.48.5.389

10.7326/0003-4819-122-2-199501150-00001

10.1002/art.1780370505

10.1002/art.1780400510

10.1002/art.1780310602

10.1136/ard.60.10.913

Kalden JR, 2001, Improved functional ability in patients with rheumatoid arthritis: longterm treatment with leflunomide versus sulfasalazine, J Rheumatol, 28, 1983

The Australian Multicentre Clinical Trial Group, 1992, Sulfasalazine in early rheumatoid arthritis, J Rheumatol, 19, 1672

10.1007/BF02208150

10.1002/art.10228

Hurst S, 2002, Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects, J Rheumatol, 29, 1639

10.1016/S0140-6736(97)01300-7

10.1002/art.21519

10.1002/art.20712

10.1002/art.20568

10.7326/0003-4819-146-6-200703200-00005

10.1056/NEJM200011303432201

10.1002/art.21405

10.1002/art.10308

Baumgartner SW, 2004, Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability, J Rheumatol, 31, 1532

Genovese MC, 2005, Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis, J Rheumatol, 32, 1232

10.1002/1529-0131(200010)43:10<2316::AID-ANR20>3.0.CO;2-6

10.1016/S0002-9343(02)01243-3

Choi HK, 2002, A cost effectiveness analysis of treatment options for methotrexate‐naive rheumatoid arthritis, J Rheumatol, 29, 1156

10.1136/ard.2005.038349

10.1016/S0140-6736(04)15640-7

10.1002/art.11142

10.7326/0003-4819-130-6-199903160-00004

10.1196/annals.1254.057

O'Dell JR, 2006, Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis, J Rheumatol, 33, 213

10.1111/j.1445-5994.2006.01170.x

10.1002/art.11027

10.1136/ard.2005.035709

10.1136/ard.2003.013052

10.1016/S0149-2918(03)80164-9

10.1136/ard.61.4.358

10.1093/rheumatology/keh508

Furst DE, 2003, Adalimumab, a fully human anti tumor necrosis factor‐α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis), J Rheumatol, 30, 2563

10.1002/art.20228

10.1136/ard.2006.051540

10.1002/art.20217

10.1016/S0140-6736(99)05246-0

10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W

10.1002/art.20159

10.1136/ard.2003.015933

10.1016/j.amjmed.2005.01.029

10.1056/NEJM200011303432202

10.1002/art.20982

10.1002/art.21655

10.1056/NEJM199901283400401

10.1136/ard.2005.044404

10.1002/art.10697

10.1002/art.20221

10.1136/ard.2005.049650

Emery P, 2006, Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health‐related quality of life, J Rheumatol, 33, 681

Genant HK, 2006, Abatacept sustains inhibition of radiographic progression over 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate: results from the long‐term extension of the AIM trial, Ann Rheum Dis, 65, 57

10.7326/0003-4819-144-12-200606200-00003

10.1056/NEJMoa032534

10.1002/art.21778

10.1136/ard.2004.029694

10.1002/art.22070

10.1002/art.21978

10.1002/art.21568

10.1002/art.20009

10.1001/jama.295.19.2275

10.1002/art.21386

10.1002/art.21137

10.1016/S0755-4982(05)83925-9

10.1086/506935

10.1136/ard.62.suppl_2.ii30

10.1056/NEJMoa011110

10.1086/421494

Perdriger A, 2006, Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice, J Rheumatol, 33, 865

10.1136/ard.2005.043166

McKendry RJ, 1988, Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a case‐control study of 131 patients, Arch Intern Med, 149, 685, 10.1001/archinte.1989.00390030137027

10.1093/rheumatology/39.12.1374

10.1093/rheumatology/39.6.655

10.1093/rheumatology/keh512

10.1007/BF02114393

10.1093/rheumatology/28.2.147

10.1007/BF00302669

Buchbinder R, 1993, Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice, J Rheumatol, 20, 639

10.1378/chest.109.4.933

10.1093/rheumatology/35.5.441

Ohosone Y, 1997, Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis, J Rheumatol, 24, 2299

10.1002/art.1780290713

Tan N, 1993, Oral methotrexate in the treatment of Felty's syndrome, J Rheumatol, 20, 599

10.1093/rheumatology/37.8.908

10.1136/ard.2004.033241

10.1136/ard.2004.023473

10.1136/ard.2004.030528

10.1136/ard.61.9.793

Louis M, 2003, Induction of autoantibodies during prolonged treatment with infliximab, J Rheumatol, 30, 2557

10.1002/art.20311

The Criteria Committee of the New York Heart Association, 1994, Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 253

10.1161/01.CIR.0000077913.60364.D2

10.1161/01.CIR.0000124490.27666.B2

10.1080/030097499750042245

10.1002/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B

Cartwright VW, 2003, Methotrexate, laboratory testing and risk of serious illness: analyses in 20,000 patients, Arthritis Rheum, 48, S428

Rau R, 1989, Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate, J Rheumatol, 16, 489

Yazici Y, 2005, Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities, Clin Exp Rheumatol, 23, 517

10.1136/ard.2004.023408

10.1093/rheumatology/29.2.120

10.1136/ard.60.6.566

Morassut P, 1989, Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis: a randomized, double blind 26‐week trial, J Rheumatol, 16, 302

Suarez‐Almazor ME, 1988, A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine) in the treatment of rheumatoid arthritis, J Rheumatol, 15, 753

10.1002/art.1780360303

10.1093/rheumatology/36.3.345

10.1093/rheumatology/37.10.1060

Cannon GW, 2004, Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD, J Rheumatol, 31, 1906

10.1002/art.20167

Sany J, 1991, Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases, J Rheumatol, 18, 1323

10.1002/art.1780330305

10.1007/BF02030344

10.1136/ard.47.8.654

10.1007/BF02330596

10.1016/0002-9343(85)90312-2

10.1002/art.1780371013

McKendry RJ, 1993, Adverse effects of low dose methotrexate therapy in rheumatoid arthritis, J Rheumatol, 20, 1850

10.1007/BF00290521

Andersen LS, 1997, Prospectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: relation to withdrawal and side effects, J Rheumatol, 24, 830

10.1093/rheumatology/33.7.651

10.1136/ard.62.4.291

10.3109/03009749509095176

Jones E, 1991, Response to sulfasalazine in rheumatoid arthritis: life table analysis of a 5‐year followup, J Rheumatol, 18, 195

10.1002/hep.1840040313

10.1016/S0011-3840(64)80003-4

10.1002/bjs.1800600817

10.1007/s10067-006-0218-1

10.1136/gut.35.4.569

Koziel MJ, 1992, Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis, J Immunol, 149, 3339, 10.4049/jimmunol.149.10.3339

10.1111/j.1478-3231.2006.01339.x

10.1128/JVI.77.4.2469-2476.2003

10.1111/j.1440-1746.2006.04559.x

Nagashima M, 2005, The ability of disease modifying antirheumatic drugs to induce and maintain improvement in patients with rheumatoid arthritis: epidemiology of DMARDs treatment in Japan, Clin Exp Rheumatol, 23, 27

Furst DE, 1989, Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis, J Rheumatol, 16, 313

BermasBL. Use of immunosuppressive drugs in pregnancy and lactation.2007. URL:http://patients.uptodate.com/topic.asp?file=tx_rheum/9876.

Ostensen M, 2006, Anti‐inflammatory and immunosuppressive drugs and reproduction, Arthritis Res Ther, 8, 209, 10.1186/ar1957

10.3109/00016348709022049

10.1046/j.1365-2133.1996.134869.x

10.1016/0002-9378(72)90824-1

10.1038/ncprheum0532

Chakravarty EF, 2003, The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes, J Rheumatol, 30, 241

10.1007/s10620-006-9452-2

10.1111/j.1572-0241.2004.30186.x

10.1111/j.1365-2036.2005.02405.x

10.1038/sj.jp.7211481

10.1093/rheumatology/kel400

10.1034/j.1600-0897.2001.d01-25.x

10.1016/j.semarthrit.2005.05.002

10.1136/gut.51.3.362

10.1136/gut.2005.065417

10.1177/107110070402500510

Den Broeder AA, 2007, Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti‐tumor necrosis factor: a large retrospective study, J Rheumatol, 34, 689

10.1002/art.21841

Shergy WJ, 2005, Infliximab and its impact on surgical outcomes in patients with rheumatoid arthritis, Ann Rheum Dis, 64, 465

10.1177/107110070302400106

Bridges SL, 1991, Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis?, J Rheumatol, 18, 984

Carpenter MT, 1996, Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy, Orthopedics, 19, 207, 10.3928/0147-7447-19960301-09

Escalante A, 1995, Risk factors for early wound complications after orthopedic surgery for rheumatoid arthritis, J Rheumatol, 22, 1844

10.1007/s00296-006-0138-z

10.1136/ard.60.3.214

10.1053/jhsu.2002.32958

Kasdan ML, 1993, Postoperative results of rheumatoid arthritis patients on methotrexate at the time of reconstructive surgery of the hand, Orthopedics, 16, 1233, 10.3928/0147-7447-19931101-10

10.1002/art.1780340204

10.1016/j.semarthrit.2006.10.003

Sany J, 1993, Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis, J Rheumatol, 20, 1129

10.1097/01.RHU.0000062514.54375.bd

Bresnihan B, 2001, Clinical experience with interleukin‐1 receptor antagonist in rheumatoid arthritis, J Clin Rheumatol, 7, S12

10.1002/art.1780390503

Chakravarty EF, 2004, The use of DMARDs in women with RA of childbearing age: a survey of practice patterns and pregnancy outcomes, J Rheumatol, 31, 401

10.1001/archinte.160.5.610

10.2165/00044011-200626020-00001

10.2165/00002018-200427050-00006

10.7326/0003-4819-141-9-200411020-00013

10.1086/339192

10.1086/338043

10.1136/ard.2005.036434

10.1093/rheumatology/kei193

Kroger AT, 2006, General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep, 55, 1

Centers for Disease Control and Prevention, 2005, Recommended adult immunization schedule: United States, October 2005‐September 2006, MMWR Morb Mortal Wkly Rep, 54, Q1–4

10.7326/0003-4819-114-12-999

Committee on Rheumatologic Care. Screening for hydroxychloroquine retinopathy.2006. URL:http://www.rheumatology.org/publications/position/hydroxyp2.asp?aud=mem.

Kaine J, 2006, Effect of adalimumab (Humira) on response to influenza virus and pneumococcal vaccines in patients with rheumatoid arthritis (RA), Ann Rheum Dis, 65, 304

Oren C, 2006, Vaccination against influenza in rheumatoid arthritis patients: the effect of rituximab on the humoral response, Arthritis Rheum, 54, S515

Corbo M, 2006, A single dose of abatacept does not prevent the development of a positive immune response to tetanus and pneumococcal vaccines, Ann Rheum Dis, 65, 184

Kapetanovic MC, 2006, Influenza vaccination as a model for testing immune modulation of anti‐TNF and methotrexate therapy in rheumatoid arthritis patients, Ann Rheum Dis, 65, 184

Centers for Disease Control and Prevention, 2003, Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection. United States, 2003, MMWR Morb Mortal Wkly Rep, 52, 735

10.1164/ajrccm.161.supplement_3.ats600

Mazurek GH, 2005, Guidelines for using the QuantiFERON‐TB Gold test for detecting Mycobacterium tuberculosis infection, United States, MMWR Recomm Rep, 54, 49

10.1016/S1473-3099(04)01206-X

10.1136/ard.62.8.791

10.1002/art.21382

10.1002/art.21734

10.1002/art.21043

10.1136/thx.2005.046797

10.1002/art.11407

10.1002/1529-0131(200101)44:1<53::AID-ANR8>3.0.CO;2-O

10.1016/j.berh.2007.02.005